Key Details from the FDA Record (NDA 021773)
- Drug Name: Byetta (exenatide synthetic) Injection
- Company: Amylin Pharmaceuticals, later acquired by AstraZeneca FDA Access DataWikipedia
- FDA Approval Date: April 28, 2005 FDA Access Data+1
- Status: Discontinued—approval was formally withdrawn as of September 3, 2025, since it is no longer marketed Public Inspection Federal RegisterGovInfo
Indication & Efficacy
- Approved Use: As an adjunctive therapy for adults with Type 2 diabetes mellitus, particularly for patients not achieving adequate glycemic control on metformin and/or sulfonylurea PMCWikipedia.
- Efficacy Highlights:
- Typically, exenatide (Byetta) reduces A1C by around 1.0% to 1.1% and helps a larger proportion of patients reach A1C ≤ 7% compared with placebo or insulin glargine in head-to-head trials AAFPPMC.
- GLP-1 receptor agonists like exenatide have shown A1C reductions between 0.7% and 2%, often accompanied by modest weight loss Wikipedia.
- Longer-acting exenatide formulations have demonstrated sustained glycemic control over years—though these findings pertain to extended-release versions (ExeOW), not the original Byetta twice-daily formulation PMCLilly Investor Relations.
Mechanism of Action
Byetta is a GLP-1 receptor agonist. It:
- Enhances glucose-dependent insulin secretion from pancreatic beta cells,
- Suppresses excessive glucagon release,
- Slows gastric emptying, and
- Helps curb appetite—leading to improved glycemic control and moderate weight loss FDA Access DataWikipedia.
Patent & Exclusivity Insights
- A core US patent US 5,424,286 covering Byetta was issued June 13, 1995, owned by John Eng and Amylin Pharmaceuticals USPTO.
- Additional patent and exclusivity protections extended into the 2010s, with AstraZeneca holding around 8 US patents filed in 2013, all of which have now expired. The estimated earliest generic launch date was November 4, 2024 Pharsight.
- Indeed, a licensing agreement settled with Teva enabled them to market a generic version of Byetta starting October 15, 2017 under agreed terms Teva Pharmaceuticals.
Discover more from सुदर्शन
Subscribe to get the latest posts sent to your email.